Walters Group bought $7.8M of ZNTL
owner at Zentalis Pharmaceuticals, Inc.. 6,459,973 shares at an average of $1.20, traded Dec 31, 2025, filed Jan 8, 2026.
Score components
- +12Role10% owner
- +25Trade size$7.8M at market
- +10Relative to holdingsHoldings up 92%
- +8Price context58% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.8%, 3m +55.6%, 6m +65.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-002567, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | POpen-market purchase Common Stock | +6,459,973 | $1.20 | $7.8M | 13,509,973 | Jan 8, 2026 |
Related signals
Other insiders at Zentalis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | ZNTLbuy Zentalis Pharmaceuticals, Inc. | Walters Group owner | $15M 4,335,000 shares | +32% | |
| 30Weak | Zentalis Pharmaceuticals, Inc. | Ingmar Bruns Chief Medical Officer | $7,998 3,297 shares | -9% | |
| 40Moderate | Zentalis Pharmaceuticals, Inc. | Julia Marie Eastland CEO & President | $21k 8,755 shares | -10% | |
| 25Weak | Zentalis Pharmaceuticals, Inc. | Vincent Vultaggio PAO and PFO | $98k 40,224 shares | -22% | |
| 10Weak | Zentalis Pharmaceuticals, Inc. | Vincent Vultaggio PAO and PFO | $7,875 3,096 shares | -2% | |
| 57Moderate | ZNTLsell Zentalis Pharmaceuticals, Inc. | Matrix Capital Management Company, LP owner | $10.0M 7,500,000 shares | -54% | |
| 31Weak | ZNTLbuy Zentalis Pharmaceuticals, Inc. | Scott Dunseth Myers director | $29k 21,000 shares | +8% | |
| 39Weak | Zentalis Pharmaceuticals, Inc. | Ingmar Bruns Chief Medical Officer | $46k 20,000 shares | +120% | |
| 48Moderate | Zentalis Pharmaceuticals, Inc. | Julia Marie Eastland CEO & President | $49k 28,500 shares | - | |
| 12Weak | Zentalis Pharmaceuticals, Inc. | Cam Gallagher President, Interim CFO | $115k 9,597 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.